Related Experiment Videos
BIO-1211 (Biogen)
1Bio-Méga/Boehringer Ingelheim Research Inc, 2100 rue Cunard, Lavel, Quebec H7S 2G5, Canada. gbolger@lav.boehringer-ingelheim.com
Idrugs : the Investigational Drugs Journal
|August 16, 2005
Summary
Biogen and Merck are developing VLA-4 (alpha4beta1) integrin antagonists for inflammatory conditions. These specific VLA-4 inhibitors offer targeted anti-inflammatory action, with Merck advancing a lead compound for asthma into Phase II trials.
Area of Science:
- Immunology
- Pharmacology
Background:
- Biogen and Merck & Co. are collaborating on novel very late antigen-4 (VLA-4) integrin antagonists.
- These compounds are being developed for the potential treatment of various inflammatory conditions.
Purpose of the Study:
- To investigate the therapeutic potential of VLA-4 antagonists.
- To evaluate the efficacy and safety of lead compounds in preclinical and clinical settings.
Main Methods:
- Development of VLA-4 (alpha4beta1) integrin antagonists.
- Phase II clinical trials for asthma indication (Merck).
- Preclinical research for other indications (Biogen).
Main Results:
- VLA-4 inhibitors demonstrate anti-inflammatory effects by blocking leukocyte adhesion.
- These inhibitors exhibit specificity without compromising basophil function.
- Merck's lead compound, BIO-1211, is in Phase II trials for asthma.
Conclusions:
- VLA-4 antagonists represent a promising class of drugs for inflammatory diseases.
- The collaborative development strategy allows for targeted indications for each company.
- Projected market entry by 2003 and significant peak sales indicate strong commercial potential.